glucagon like peptide 1 glp1 7 36 molecule the glucagon like peptide 1 receptor has a strong effect on the management of type 2 diabetes mellitus

New Research Findings, Diabetes, IDO,

One Molecule, Two Effects: A New Drug Concept to Treat Obesity and Type 2 Diabetes

A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signalling pathway as a “door opener” and delivers an…

Professor Timo Müller

Awards & Grants, Diabetes, IDO,

Timo Müller Receives the ADA 2026 Outstanding Scientific Achievement Award

The American Diabetes Association (ADA) has announced the recipients of this year's National Scientific and Health Care Achievement Awards. Among this year’s awardees is Prof. Timo Müller, Director of the Institute for Diabetes and Obesity (IDO) at…

Distribution of proteins in cells

AI, New Research Findings, Diabetes, IDO,

C-COMPASS: AI-Based Software Maps Proteins and Lipids Within Cells

A new tool developed by Helmholtz Munich and the German Center for Diabetes Research and the University of Bonn makes spatial proteomics and lipidomics easier to use – no coding required. C-COMPASS allows scientists to profile where proteins and…

Diabinfo im Dialog

Events, Public Engagement, Diabetes, HI-MAG, IDO,

diabinfo in Dialogue: Obesity and Diabetes – Evolving Approaches to Prevention and Treatment

The medical treatment of obesity and type 2 diabetes is currently undergoing a significant transformation. Innovative drugs such as semaglutide and tirzepatide – often referred to as "weight-loss injections" – mimic the action of specific gut…

Obesity weight loss

New Research Findings, Diabetes, IDO,

GIP Receptor: Activation and Blockade Support Weight Loss

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that not only activate the GIP receptor (agonists) but…

The Lancet Diabetes & Endocrinology Commission on Clinical Obesity

Diabetes, HI-MAG, IDO,

Re-Defining Obesity as a Disease

A new report of the Commission on Clinical Obesity, published in The Lancet Diabetes & Endocrinology and endorsed by over 75 medical organizations, has introduced a transformative framework that addresses the limitations of traditional BMI-based…